Pharming Group (PHAR) Revenue & Revenue Breakdown
Pharming Group Revenue Highlights
Latest Revenue (Y)
$245.32M
Latest Revenue (Q)
$55.46M
Main Geography (Y)
UNITED STATES
Pharming Group Revenue by Period
Pharming Group Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $245.32M | 19.30% |
| 2022-12-31 | $205.62M | 8.31% |
| 2021-12-31 | $189.85M | -16.88% |
| 2020-12-31 | $228.39M | 20.63% |
| 2019-12-31 | $189.33M | 22.49% |
| 2018-12-31 | $154.58M | 43.77% |
| 2017-12-31 | $107.52M | 544.06% |
| 2016-12-31 | $16.69M | 41.01% |
| 2015-12-31 | $11.84M | -54.05% |
| 2014-12-31 | $25.76M | 172.60% |
| 2013-12-31 | $9.45M | -32.67% |
| 2012-12-31 | $14.04M | 261.10% |
| 2011-12-31 | $3.89M | 410.06% |
| 2010-12-31 | $762.07K | -51.47% |
| 2009-12-31 | $1.57M | 69.88% |
| 2008-12-31 | $924.35K | -8.12% |
| 2007-12-31 | $1.01M | 418.54% |
| 2006-12-31 | $194.01K | -59.55% |
| 2005-12-31 | $479.68K | - |
Pharming Group generated $245.32M in revenue during NA 2023, up 19.30% compared to the previous quarter, and up 158.70% compared to the same period a year ago.
Pharming Group Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $55.46M | -32.26% |
| 2023-12-31 | $81.87M | 22.81% |
| 2023-09-30 | $66.66M | 21.43% |
| 2023-06-30 | $54.90M | 29.04% |
| 2023-03-31 | $42.54M | -22.12% |
| 2022-12-31 | $54.62M | 0.71% |
| 2022-09-30 | $54.24M | 8.16% |
| 2022-06-30 | $50.15M | 7.57% |
| 2022-03-31 | $46.62M | 1.90% |
| 2021-12-31 | $45.75M | -7.46% |
| 2021-08-05 | $49.44M | -0.61% |
| 2021-06-30 | $49.74M | 17.73% |
| 2021-03-31 | $42.25M | -39.84% |
| 2020-12-31 | $70.23M | 20.01% |
| 2020-09-30 | $58.52M | 29.28% |
| 2020-06-30 | $45.27M | -16.73% |
| 2020-03-31 | $54.37M | 0.00% |
| 2019-12-31 | $54.37M | 17.29% |
| 2019-09-30 | $46.35M | -5.51% |
| 2019-06-30 | $49.06M | 24.01% |
| 2019-03-31 | $39.56M | -2.03% |
| 2018-12-31 | $40.37M | -11.19% |
| 2018-09-30 | $45.46M | 40.34% |
| 2018-06-30 | $32.39M | -10.89% |
| 2018-03-31 | $36.35M | -11.15% |
| 2017-12-31 | $40.91M | 29.66% |
| 2017-09-30 | $31.55M | 70.23% |
| 2017-06-30 | $18.54M | 12.19% |
| 2017-03-31 | $16.52M | 137.90% |
| 2016-12-31 | $6.94M | 78.86% |
| 2016-09-30 | $3.88M | 15.65% |
| 2016-06-30 | $3.36M | 33.80% |
| 2016-03-31 | $2.51M | 7.05% |
| 2015-12-31 | $2.34M | -27.85% |
| 2015-09-30 | $3.25M | -5.96% |
| 2015-06-30 | $3.46M | 94.10% |
| 2015-03-31 | $1.78M | -89.74% |
| 2014-12-31 | $17.34M | 1229.98% |
| 2014-09-30 | $1.30M | 16.43% |
| 2014-06-30 | $1.12M | -21.07% |
| 2014-03-31 | $1.42M | 61.80% |
| 2013-12-31 | $877.00K | -17.42% |
| 2013-09-30 | $1.06M | -75.98% |
| 2013-06-30 | $4.42M | 813.43% |
| 2013-03-31 | $484.00K | -94.21% |
| 2012-12-31 | $8.36M | 1627.89% |
| 2012-09-30 | $484.00K | -45.50% |
| 2012-06-30 | $888.00K | 1.14% |
| 2012-03-31 | $878.00K | 3.17% |
| 2011-12-31 | $851.00K | 1.67% |
| 2011-09-30 | $837.00K | 24.00% |
| 2011-06-30 | $675.00K | 6.13% |
| 2011-03-31 | $636.00K | -755.67% |
| 2010-12-31 | $-97.00K | -136.60% |
| 2010-09-30 | $265.00K | 33.84% |
| 2010-06-30 | $198.00K | -4.35% |
| 2010-03-31 | $207.00K | -63.36% |
| 2009-12-31 | $565.00K | 208.74% |
| 2009-09-30 | $183.00K | -25.00% |
| 2009-06-30 | $244.00K | 134.62% |
| 2009-03-31 | $104.00K | - |
Pharming Group generated $55.46M in revenue during Q1 2024, up -32.26% compared to the previous quarter, and up 101.53% compared to the same period a year ago.
Pharming Group Revenue Breakdown
Pharming Group Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| UNITED STATES | $239.11M | $200.10M | $177.39M | - |
| Rest Of The World, Excluding US And Europe | - | $616.00K | $519.00K | $1.10M |
| Europe | - | $4.92M | $4.93M | $7.21M |
Pharming Group's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (100.00%).
Pharming Group Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PHAR | Pharming Group | $245.32M | $55.46M |
| FENC | Fennec Pharmaceuticals | $21.64M | $25.26M |
| JANX | Janux Therapeutics | $8.08M | $1.25M |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| VRCA | Verrica Pharmaceuticals | $5.12M | $3.83M |
| PRTC | PureTech Health | $3.33M | $178.57K |
| FIXX | Q32 Bio | $1.16M | - |
| OPT | Opthea | $108.41K | $61.27K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| RZLT | Rezolute | - | - |
| LIAN | LianBio | - | - |
| ELYM | Eliem Therapeutics | - | - |
| ACRV | Acrivon Therapeutics | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| LRMR | Larimar Therapeutics | - | - |
| PRDS | Pardes Biosciences | - | - |
| GNTA | Genenta Science S.p.A. | - | - |
PHAR Revenue FAQ
What is Pharming Group’s yearly revenue?
Pharming Group's yearly revenue for 2023 was $245.32M, representing an increase of 19.30% compared to 2022. The company's yearly revenue for 2022 was $205.62M, representing an increase of 8.31% compared to 2021. PHAR's yearly revenue for 2021 was $189.85M, representing a decrease of -16.88% compared to 2020.
What is Pharming Group’s quarterly revenue?
Pharming Group's quarterly revenue for Q1 2024 was $55.46M, a -32.26% decrease from the previous quarter (Q4 2023), and a 30.36% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $81.87M, a 22.81% increase from the previous quarter (Q3 2023), and a 49.88% increase year-over-year (Q4 2022). PHAR's quarterly revenue for Q3 2023 was $66.66M, a 21.43% increase from the previous quarter (Q2 2023), and a 22.90% increase year-over-year (Q3 2022).
What is Pharming Group’s revenue growth rate?
Pharming Group's revenue growth rate for the last 3 years (2021-2023) was 29.21%, and for the last 5 years (2019-2023) was 29.57%.